Overview Press Releases Events and Presentations Financials and Filings Stock Information Corporate Governance FAQs Email Alerts Rezdiffra Approval Call Mar 14, 2024 at 5:15 PM EDT Listen to Webcast Supporting Materials Rezdiffra Approval Presentation 1.1 MB Madrigal Pharmaceuticals Announces FDA Approval of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic Nonalcoholic Steatohepatitis (NASH) with Moderate to Advanced Liver Fibrosis
Rezdiffra Approval Call Mar 14, 2024 at 5:15 PM EDT Listen to Webcast Supporting Materials Rezdiffra Approval Presentation 1.1 MB Madrigal Pharmaceuticals Announces FDA Approval of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic Nonalcoholic Steatohepatitis (NASH) with Moderate to Advanced Liver Fibrosis